Medication

Is Ketamine a Psychedelic Drug?

Ketamine is not a classic psychedelic like psilocybin or LSD. It is a dissociative anesthetic that works mainly by blocking the brain's NMDA receptors. At lower doses it can produce dream-like, detached states that feel psychedelic to many people, which is why the label keeps getting debated. The short version: ketamine sits in its own drug class, but the experience it creates overlaps with what psychedelics do. Below we cover how it works, how it compares to classic psychedelics, and how its FDA-approved form is used for depression.

Written by Angel Rivera, MD , Board-Certified Psychiatrist

Last updated 2026-07-04

Is ketamine a psychedelic drug?

The short answer is that ketamine is best classified as a dissociative anesthetic, not a classic psychedelic. Classic psychedelics such as psilocybin, LSD, and mescaline work primarily by activating a specific serotonin receptor. Ketamine does something different, so pharmacologically it sits in its own category.

That said, at the lower, sub-anesthetic doses used for mental health, ketamine can produce altered perception, a sense of detachment from the body, and dream-like experiences that feel psychedelic to many people. For that reason, researchers sometimes call it an atypical or non-classic psychedelic. So the honest answer is nuanced: it is not a classic psychedelic by mechanism, but it can create psychedelic-like effects.

What kind of drug ketamine actually is

Ketamine was developed in the 1960s as an anesthetic and is still widely used for anesthesia and pain, including in emergency medicine and pediatrics, because it relieves pain and induces a trance-like state without shutting down breathing the way some anesthetics do. In the United States it is a Schedule III controlled substance, reflecting an accepted medical use alongside a potential for misuse.

The term dissociative refers to the characteristic experience it produces: a feeling of being disconnected from your body, surroundings, or sense of self. Other dissociative drugs include PCP and dextromethorphan. Ketamine's more recent claim to fame is its rapid antidepressant effect, which can appear within hours, in contrast to standard antidepressants that take weeks.

How ketamine works in the brain

Ketamine's primary action is blocking the NMDA receptor, a docking site for the neurotransmitter glutamate, which is the brain's main excitatory signal. By blocking NMDA receptors on certain neurons, ketamine sets off a chain reaction that ends up increasing glutamate signaling elsewhere, particularly at receptors called AMPA receptors.

That surge is thought to trigger the release of growth factors like BDNF and to activate pathways that promote synaptogenesis, the formation of new connections between neurons. Many researchers believe this rapid boost in neuroplasticity, the brain's ability to rewire itself, is what underlies ketamine's fast antidepressant effect. This glutamate-based mechanism is completely different from the serotonin-receptor activation behind classic psychedelics.

Ketamine vs classic psychedelics

Lining ketamine up against classic psychedelics makes the differences concrete. They feel loosely similar to users at times, but they are distinct drugs with distinct biology and legal status.

  • Mechanism: ketamine blocks NMDA (glutamate) receptors; classic psychedelics activate the 5-HT2A serotonin receptor.
  • Drug type: ketamine is a dissociative anesthetic; psilocybin and LSD are serotonergic psychedelics.
  • Experience: ketamine causes dissociation and detachment; classic psychedelics cause vivid visual and perceptual changes.
  • Legal status: ketamine is Schedule III with accepted medical uses; psilocybin and LSD are Schedule I federally.
  • Medical use: an esketamine nasal spray is FDA-approved for depression; classic psychedelics remain investigational in the U.S.
  • Duration: ketamine's effects are relatively short, often under an hour or two; LSD can last many hours.

Ketamine and esketamine for depression

Ketamine's antidepressant potential has driven two parallel tracks. The first is intravenous ketamine given off-label in clinics for treatment-resistant depression, which is not FDA-approved for that use but is supported by a growing body of research. The second is esketamine, the S-molecule of ketamine, sold as the nasal spray Spravato.

The FDA first approved esketamine in March 2019 for treatment-resistant depression when used together with an oral antidepressant, and in 2020 added an indication for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior. In January 2025 the FDA cleared Spravato as a standalone monotherapy for treatment-resistant depression, so it can now be prescribed with or without an oral antidepressant.

Spravato is dispensed only through a restricted REMS program. You cannot pick it up at a pharmacy or take it home. Instead you self-administer the spray under a clinician's supervision in a certified healthcare setting, then stay to be monitored for at least two hours after each dose because of the risk of sedation and dissociation. That structure is a practical thing to plan for: treatment appointments run several hours and usually require someone else to drive you home.

What a ketamine experience feels like

At the low doses used for depression, people often describe feeling detached from their body, a floating or dream-like sensation, altered sense of time, and sometimes mild visual distortions. Some find it pleasant and insightful, while others find the dissociation unsettling, which is one reason clinical settings include support and monitoring.

These effects are temporary and typically fade within an hour or two of a treatment session. The antidepressant benefit, when it occurs, can outlast the immediate experience, which is why treatment is usually given as a series of sessions rather than a single dose.

Risks and why supervision matters

Ketamine is not risk-free. Short-term, it can raise blood pressure and heart rate, cause nausea, and produce disorientation, which is why blood pressure is monitored during clinical use. Used recreationally and repeatedly at high doses, it carries risks of bladder damage, cognitive problems, and psychological dependence.

This gap between supervised medical use and unsupervised recreational use is the whole point of the caution. In a clinic, dose, setting, and monitoring are controlled, and treatment is paired with mental health care. On the street, none of that applies, and the same drug becomes considerably more dangerous. If you are considering ketamine for depression, it should be through a licensed provider who can assess whether it fits your situation. If you are having thoughts of suicide, call or text 988 for the Suicide and Crisis Lifeline before pursuing any treatment on your own.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a licensed clinician for questions about your mental health. If you or someone you know is in crisis, call or text 988 (Suicide & Crisis Lifeline).

Frequently asked questions

Is ketamine considered a psychedelic?

Not a classic one. Ketamine is a dissociative anesthetic that blocks NMDA receptors, unlike classic psychedelics such as psilocybin and LSD, which act on serotonin receptors. Because it can cause psychedelic-like effects, some researchers call it an atypical or non-classic psychedelic.

How is ketamine different from psilocybin or LSD?

The main difference is mechanism. Ketamine works on the brain's glutamate system by blocking NMDA receptors, while psilocybin and LSD activate the 5-HT2A serotonin receptor. Ketamine also has accepted medical uses and is Schedule III, whereas those psychedelics are Schedule I.

Is ketamine FDA-approved for depression?

Esketamine, a form of ketamine sold as the nasal spray Spravato, is FDA-approved for treatment-resistant depression, including as a standalone therapy since January 2025. Intravenous ketamine itself is used off-label for depression and is not FDA-approved for that purpose.

What happens during a Spravato appointment?

You self-administer the nasal spray in a certified clinic while a healthcare provider observes, then stay to be monitored for at least two hours before leaving. The medication is not dispensed for home use, and most clinics ask you to arrange a ride home rather than drive afterward.

Why must esketamine be given in a clinic?

Because of risks like sedation, dissociation, and misuse potential, Spravato is only available through a restricted REMS program. It must be administered in a certified healthcare setting where you are monitored for a period after each dose.

Is ketamine safe?

Under medical supervision at controlled doses, ketamine has an established safety profile, though it can temporarily raise blood pressure and cause disorientation. Recreational, high-dose, or repeated unsupervised use carries risks including bladder damage, cognitive effects, and dependence.

References

  1. MedlinePlus (NIH) — Esketamine Nasal Spray (Spravato): uses, REMS program, and monitoring
  2. NCBI (PMC) — Ketamine, Esketamine, and Arketamine: Mechanisms of Action
  3. Nature (Molecular Psychiatry) — Mechanisms of Ketamine Action as an Antidepressant
  4. DEA — Ketamine Drug Fact Sheet

Take the next step

Ready to start feeling better?

Take our brief matching assessment and connect with a licensed therapist who's right for you within 48 hours.

Free matching • Cancel anytime • Secure & confidential